Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study

A Tourbah1, A Clapin, O Gout

  • 1Fédération de Neurologie and Université Paris VI, INSERM U134 et CJF Pathologie de la Myéline, Hôpital de la Salpêtrière, Paris, France.

Archives of Neurology
|April 30, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Positive effect of evobrutinib in CNS remyelination models and lack of synergy with clemastine-A dose response study.

Multiple sclerosis journal - experimental, translational and clinical·2025
Same author

Deleterious functional consequences of perfluoroalkyl substances accumulation into the myelin sheath.

Environment international·2023
Same author

A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.

Journal of neurology·2023
Same author

Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria.

Revue neurologique·2022
Same author

Health related quality of life and perceived social support in French and Lebanese MS patients: A comparative study.

Multiple sclerosis and related disorders·2022
Same author

Microglia-neuron interaction at nodes of Ranvier depends on neuronal activity through potassium release and contributes to remyelination.

Nature communications·2021

Patients with multiple sclerosis (MS) and autoimmune features, including antinuclear antibodies, show similar disease progression to those without these abnormalities. These findings suggest MS patients with autoimmune markers should be included in clinical trials.

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • The presence of other autoimmune abnormalities in MS patients is not well understood.
  • Investigating these co-occurrences is crucial for understanding disease heterogeneity.

Purpose of the Study:

  • To assess the prevalence of clinical and biological autoimmune markers in MS patients.
  • To compare the clinical and MRI features and disease evolution in MS patients with and without autoimmune abnormalities.
  • To determine if autoimmune features impact MS prognosis or trial eligibility.

Main Methods:

  • Prospective study of 161 patients diagnosed with probable or definite MS.

Related Experiment Videos

  • Patients were evaluated for clinical signs and biological markers of autoimmune diseases, including antinuclear and antiphospholipid antibodies.
  • A subset of 64 patients was followed for 4-5 years for clinical and imaging outcomes.

    • Main Results:

    • Over half (52.1%) of MS patients exhibited at least one autoimmune abnormality.
    • Among confirmed MS cases, 13.3% had general autoimmune signs, 26% had positive antinuclear antibodies, and 6.2% had positive antiphospholipid antibodies.
    • No significant differences in disease onset, symptoms, neurological findings, or disease course were observed between MS patients with and without autoimmune features.

    Conclusions:

    • Autoimmune features, including low-titer antinuclear antibodies and antiphospholipid antibodies, do not alter the clinical presentation or progression of MS.
    • MS patients with co-occurring autoimmune abnormalities exhibit similar characteristics to those without.
    • These findings support the inclusion of MS patients with autoimmune features in clinical trials, ensuring broader representation and generalizability of results.